Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Jitske van den Bulk (17142147) (author)
Andere auteurs:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
door: Jitske van den Bulk (17142147)
Gepubliceerd in: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
door: Maria Lozano-Rabella (15056515)
Gepubliceerd in: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
door: Ankita Mitra (17141783)
Gepubliceerd in: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
door: Ankita Mitra (17141783)
Gepubliceerd in: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
door: Ankita Mitra (17141783)
Gepubliceerd in: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
door: Wei Liu (20030)
Gepubliceerd in: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
door: Christine Pich-Bavastro (16509238)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
door: Rohit Thummalapalli (17314483)
Gepubliceerd in: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
door: Wei Liu (20030)
Gepubliceerd in: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
door: Wei Liu (20030)
Gepubliceerd in: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
door: Wei Liu (20030)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_23u55q7ueleb5fqjfcmo2sbcie